27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting Download PDF Post navigationPreviousPrevious post:Success of the capital increase by private placement for an amount of 15 million eurosNextNext post:Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual MeetingRelated PostsUpdate on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)June 26, 2023AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037June 1, 2023AB Science to hold its Annual General Meeting of Shareholders on June 30, 2023May 30, 2023AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterMay 9, 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)June 26, 2023
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037June 1, 2023
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development SummitMay 17, 2023
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letterMay 9, 2023
